按品牌選擇
 |
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評(píng)論] [本類其他產(chǎn)品] [本類其他供應(yīng)商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷(xiāo)售商： TargetMol中國(guó) | 查看該公司所有產(chǎn)品 >> |
Product Introduction
Bioactivity
英文名: Levcromakalim
描述: Levcromakalim (BRL 38227) 是 一種 ATP 敏感性的 K+通道 (KATP) 激活劑。
體外活性: Levcromakalim inhibits spontaneous contractions completely in a glibenclamide-sensitive manner. LevCromakalim (5 μM) inhibits spontaneous contractions, which are recovered by glibenclamide. Levcromakalim (1, 5 and 10 μM) inhibits phasic contractions to 34±21.1%, 20.1±20.0% and 0% of the control. Glibenclamide reverses the inhibition of spontaneous isometric contractions caused by LevCromakalim (5 μM) to 84±1.5% of the control. Levcromakalim (20 and 100 μM) also inhibits oxytocin (OXT) (10 nM)-induced phasic contractions to 34±21.4% and 14±12.6% of the control [2]. LevCromakalim induces dose-dependent relaxation in both the young and old mesenteric artery (MAs); there is no difference in relaxation with age. However, the relaxation is markedly reduced in response to the high-salt (HS) diet in the old MAs (P<0.05). Maximum dilations to Levcromakalim (10-4 M) are 97 ± 3% in the young MAs versus 98 ± 1% in the young salt arteries, while dilations are 99±0.7% in the old MAs when compared with 85 ± 5% in the old salt arteries (P<0.05) [3].
存儲(chǔ)條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : Insoluble
DMSO : 50 mg/mL (174.62 mM )
關(guān)鍵字: Potassium Channel | KcsA | BRL38227 | Inhibitor | Levcromakalim | inhibit | BRL-38227 | Cromakalim
相關(guān)產(chǎn)品: Vernakalant Hydrochloride | RY785 | APD668 | ML213 | Topiramate | NS19504 | Gliquidone | A2793 | Acetohexamide | Taurocholic acid sodium salt hydrate
相關(guān)庫(kù): Ion Channel Inhibitor Library | Potassium Channel Blocker Library | Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | NO PAINS Compound Library | Bioactive Compound Library
Bioactivity
英文名: Levcromakalim
描述: Levcromakalim (BRL 38227) 是 一種 ATP 敏感性的 K+通道 (KATP) 激活劑。
體外活性: Levcromakalim inhibits spontaneous contractions completely in a glibenclamide-sensitive manner. LevCromakalim (5 μM) inhibits spontaneous contractions, which are recovered by glibenclamide. Levcromakalim (1, 5 and 10 μM) inhibits phasic contractions to 34±21.1%, 20.1±20.0% and 0% of the control. Glibenclamide reverses the inhibition of spontaneous isometric contractions caused by LevCromakalim (5 μM) to 84±1.5% of the control. Levcromakalim (20 and 100 μM) also inhibits oxytocin (OXT) (10 nM)-induced phasic contractions to 34±21.4% and 14±12.6% of the control [2]. LevCromakalim induces dose-dependent relaxation in both the young and old mesenteric artery (MAs); there is no difference in relaxation with age. However, the relaxation is markedly reduced in response to the high-salt (HS) diet in the old MAs (P<0.05). Maximum dilations to Levcromakalim (10-4 M) are 97 ± 3% in the young MAs versus 98 ± 1% in the young salt arteries, while dilations are 99±0.7% in the old MAs when compared with 85 ± 5% in the old salt arteries (P<0.05) [3].
存儲(chǔ)條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : Insoluble
DMSO : 50 mg/mL (174.62 mM )
關(guān)鍵字: Potassium Channel | KcsA | BRL38227 | Inhibitor | Levcromakalim | inhibit | BRL-38227 | Cromakalim
相關(guān)產(chǎn)品: Vernakalant Hydrochloride | RY785 | APD668 | ML213 | Topiramate | NS19504 | Gliquidone | A2793 | Acetohexamide | Taurocholic acid sodium salt hydrate
相關(guān)庫(kù): Ion Channel Inhibitor Library | Potassium Channel Blocker Library | Anti-Cancer Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | NO PAINS Compound Library | Bioactive Compound Library
手機(jī)版：左色滿卡林
- 中國(guó)生物化學(xué)與分子生物學(xué)會(huì)2025全國(guó)學(xué)術(shù)大會(huì)招商函
- MCE推出生命科學(xué)文獻(xiàn)有投必獎(jiǎng)活動(dòng)(腫瘤與癌癥)
- 睿通生物推出新品ML19熔融石英折射率匹配液
- MCE直播：同位素標(biāo)記物示蹤劑與定量?jī)?nèi)標(biāo)品的探索
- MCE邀您參加2024年滿意度有獎(jiǎng)?wù){(diào)查&感恩節(jié)回饋活動(dòng)
- MCE暖冬鉅惠：染料、siRNA65折，享1.5倍牌價(jià)積分
- MCE中國(guó)11月展會(huì)預(yù)告: 蘇州生物藥創(chuàng)新開(kāi)發(fā)峰會(huì)等
- MCE直播：癌癥中的炎癥反應(yīng)&細(xì)胞焦亡的思路與方法
- 放射性核素RDC在腫瘤診斷與治療中應(yīng)用和發(fā)展前景
- FITC-xtra 異硫氰酸熒光素的優(yōu)勢(shì)及實(shí)驗(yàn)方案步驟
- α-淀粉酶測(cè)定試劑盒 (Ceralpha Method)原理與使用
- 納米管介導(dǎo)的線粒體轉(zhuǎn)移在腫瘤免疫治療研究中的應(yīng)用
- 分子動(dòng)力學(xué)模擬技術(shù)在藥物研發(fā)領(lǐng)域的應(yīng)用前景及核心原理
- 紅霉素MTS藥敏紙條助力抗擊耐藥精準(zhǔn)檢測(cè)
- 大腸桿菌不耐熱腸毒素(LT)試劑盒使用說(shuō)明書(shū)
- 蛋白降解技術(shù)AUTOTAC、第一代和第二代AUTAC的作用機(jī)制
更多
瀏覽其他公司同類產(chǎn)品
瀏覽其他公司同類產(chǎn)品
Copyright(C) 1998-2025 生物器材網(wǎng) 電話：021-64166852;13621656896 E-mail：[email protected]